Bank of America increased price targets for AbbVie to $289 and Johnson & Johnson to $278, maintaining Buy and Neutral ratings respectively. AbbVie is favored due to its strong growth potential, robust pipeline, and attractive valuation at 16 times forward earnings versus J&J's 21 times. Both companies are navigating patent cliffs with new drug launches and acquisitions, supporting dividend growth. Upcoming catalysts include J&J's business review and AbbVie's U.S. decision on Skyrizi dosing, making AbbVie more appealing for long-term investors.
AbbVie shares are trading near their 52-week high at USD 266.00, up 1.04% on Pluang, with a dividend yield of 2.63% as of Sep 30, 2026 18:15 WIB. Johnson & Johnson is priced at USD 267.32, slightly down 0.09%, with a 2% dividend yield and a 94% Sell order activity on Pluang at the same time.
AbbVie announced positive Phase 1 results for ABBV-295, a long-acting amylin analog for obesity treatment, showing meaningful weight loss of up to 9.8% over 12-13 weeks with weekly, biweekly, and monthly dosing options. The drug demonstrated a half-l...
AbbVie announced positive Phase 2 results for zumilokibart, a monoclonal antibody targeting IL-13, in adults with moderate-to-severe atopic dermatitis. All dose regimens met the primary endpoint with significant improvements in skin severity and itch...
AbbVie presented 60 abstracts at the 2026 European Academy of Dermatology and Venereology Congress, showcasing new data on its dermatology portfolio including approved drugs risankizumab (SKYRIZI) and upadacitinib (RINVOQ), as well as investigational...
AbbVie has formed a new collaboration with Valkai to enhance its artificial intelligence (AI) capabilities in clinical development. This partnership aims to improve efficiency in clinical research, accelerate insight generation, and reduce drug devel...
AbbVie announced FDA approval of JUVMO™ (tavapadon), the first selective D1/D5 receptor agonist for treating adults with Parkinson's disease. JUVMO offers a novel approach to motor symptom control, improving daily functioning and increasing 'on' time...
